Should You Subscribe to the IPO of Hinge Health Inc?

The Offer

Company Overview

Hinge Health (HNGE) is a digital health company focused on musculoskeletal (MSK) care, utilizing AI-driven technology to automate personalized treatment for joint and muscle conditions, ranging from acute injuries to post-surgical rehabilitation, as of May 16, 2025. Its platform integrates AI-powered motion tracking, a proprietary FDA-cleared wearable device, and an AI-supported care team to reduce pain, improve function, and lower surgery rates, achieving a 95% reduction in human care hours compared to traditional therapy while enhancing member satisfaction. By addressing healthcare cost challenges through novel billing methods and partnerships with employers and health plans, HNGE delivers accessible, scalable, and equitable MSK care, positioning itself as a leader in improving clinical outcomes and reducing costs in the MSK market.

Key Highlights

Primary Offering:

13,666,000 shares (Option to purchase additional 2,049,309 shares of Class A common stock offered by the selling stockholders).

Use of proceeds:

• Estimated Net Proceeds from Hinge Health’s Initial Public Offering: Hinge Health (HNGE) anticipates receiving net proceeds of approximately USD 230.7 million from its initial public offering, based on an assumed offering price of USD 30.00 per share of Class A common stock, as detailed in its prospectus dated May 16, 2025. This estimate, derived from the midpoint of the price range, accounts for deductions of estimated underwriting discounts, commissions, and offering expenses, with no proceeds allocated to the company from shares sold by selling stockholders. Variations in the offering price or share volume could significantly impact the proceeds, with a USD 1.00 price change adjusting the net proceeds by approximately USD 8.0 million, and a 1.0 million share change altering the proceeds by approximately USD 28.3 million, assuming other variables remain constant.
• Strategic Objectives and Allocation of Proceeds: The primary objectives of this offering for Hinge Health include enhancing capitalization, increasing financial flexibility, establishing a public market for its Class A common stock, and facilitating access to public equity markets for both the company and its stockholders, while also enabling an orderly share distribution for selling stockholders. A substantial portion of the net proceeds, approximately USD 268.2 million, will be allocated to satisfy tax withholding and remittance obligations related to the RSU Net Settlement, based on the vesting of 16,826,031 shares underlying RSUs and PRSUs at the assumed offering price and a 50.7% tax withholding rate. A USD 1.00 fluctuation in the share price could adjust this obligation by approximately USD 8.5 million, and future net settlements of additional RSUs and PRSUs may further utilize proceeds for similar tax obligations.
• Future Utilization and Flexibility of Remaining Proceeds: Hinge Health plans to allocate any remaining net proceeds primarily toward general corporate purposes, including working capital and the funding of growth strategies outlined in its prospectus, with potential investments in complementary businesses, products, or technologies, though no specific agreements for such acquisitions exist as of May 16, 2025. The company retains broad discretion over the use of these proceeds, reflecting its current business conditions and strategic plans, and may invest the funds in short-term, investment-grade, interest-bearing instruments such as government securities and money-market funds pending their deployment. This approach ensures Hinge Health maintains financial agility to support its mission of advancing AI-driven musculoskeletal care while adapting to evolving operational needs.

Dividend policy:

Hinge Health (HNGE) has not declared or paid cash dividends on its capital stock and intends to retain future earnings to support business operations, with no plans to distribute dividends in the foreseeable future, as stated in its financial policy update on May 16, 2025. The decision to declare dividends will be at the discretion of the board of directors, contingent on factors such as operational results, financial condition, capital needs, contractual obligations, and broader business conditions, ensuring alignment with applicable laws. Should a dividend be declared while Series E preferred stock remains outstanding, these shares are entitled to receive a dividend at least equal to that payable if converted into common stock, prioritizing their dividend rights in such scenarios.

Hinge Health’s Industry Context and Market Opportunities (HNGE)

• Prevalence and Impact of MSK Conditions: Musculoskeletal (MSK) conditions affect an estimated 1.7 billion people globally, with 40% of U.S. adults impacted in 2021, according to the WHO Estimator, making them a leading cause of disability and significantly diminishing quality of life, mental well-being, and work capacity, as reported on May 16, 2025. The MSK Care 2024 Survey, conducted by Hinge Health with a third-party firm, revealed that chronic and acute MSK pain creates a debilitating cycle of fear, depression, and activity avoidance, with barriers to traditional physical therapy including cost, access, and the complexity of pain management, underscoring the urgent need for innovative, accessible care solutions to address these widespread challenges.
• Economic Burden and Inefficiencies in MSK Care: The economic toll of MSK conditions in the U.S. is substantial, with direct medical costs reaching USD 661 billion in 2023 and indirect costs, such as productivity losses, adding USD 624 billion, totaling a USD 1.3 trillion burden, as per the MSK TAM Report commissioned by Hinge Health. MSK conditions account for one in seven healthcare dollars spent, with 74% of employers citing them as a top driver of costs in 2024, according to Business Group on Health. Current MSK care approaches are often inaccessible, costly, and incomplete, driving avoidable surgeries—62% of 2022 MSK costs per Health Claims Data—despite evidence favoring conservative care like physical therapy, which only 9% of U.S. adults utilized in 2023 due to systemic barriers highlighted in the Hinge Health People in Pain Survey.
• Market Opportunity and Strategic Expansion for Hinge Health: Hinge Health is well-positioned to address a USD 27 billion addressable market in the U.S., including USD 10 billion from self-insured employers, USD 8 billion from fully-insured employers and Medicare Advantage, and USD 9 billion from government programs like Medicare and Medicaid, covering over 327 million lives, as outlined in its market analysis. The company is expanding internationally, starting with Canada in Q3 2024 and planning European rollout in 2025, targeting multinational clients and non-U.S. employers to support global employees, while new programs like women’s pelvic health and menopause-focused MSK care address underserved segments, further expanding its market reach. With an aging population and a shrinking pool of physical therapists, Hinge Health’s AI-driven, scalable platform offers a sustainable solution to meet rising demand and transform MSK care delivery.

Financial Highlights (Results of Operations) (Expressed in USD)

• Client Base Growth and Retention Strategies: Hinge Health (HNGE) has significantly expanded its client base, growing from 1,650 clients in 2023 to 2,250 by December 31, 2024, increasing contracted lives from 16 million to 20 million, as reported on May 16, 2025. This growth is driven by adding new clients through strategic partnerships that streamline sales processes and by retaining existing clients, with a 98% retention rate and a client NPS of 87, reflecting high satisfaction. The company’s focus on entering new markets like fully-insured employers and Medicare Advantage, alongside its efficient sales model, supports sustained growth, though it must continue to optimize client acquisition costs to maintain financial performance.
• Member Expansion within Existing Clients: Hinge Health enhances its reach by increasing member enrollments within existing clients, focusing on new product adoption, targeted interventions, brand awareness, and partnerships, achieving a Net Dollar Retention (NDR) of 117% and an annual yield of 3.4% by December 31, 2024. Programs like women’s pelvic health and fall prevention, alongside tools like HingeConnect, which uses AI to target high-risk members, have driven engagement, with marketing initiatives boosting membership applications by 62% year-over-year. These efforts not only expand the member base but also improve client ROI by reducing MSK-related costs, positioning Hinge Health to deepen its impact within its client ecosystems.
• Innovation, Market Expansion, and Operational Efficiency: The company prioritizes continuous innovation, expanding its MSK care programs to cover 16 affected areas by 2024 and introducing technologies like TrueMotion and Enso to enhance accessibility and reduce costs, with over 75% of eligible lives adopting new programs like women’s pelvic health. Hinge Health is also pursuing international expansion, starting with Canada in 2024 and planning for Europe in 2025, while streamlining operations through a 2024 restructuring plan that reduced its workforce by 10%, aligning resources with priorities. These initiatives, combined with a 50% revenue increase to USD 123.8 million in Q1 2025 and a gross margin improvement to 81%, underscore Hinge Health’s ability to navigate macroeconomic challenges and capitalize on the growing demand for digital MSK care.
• Income Statement Insights and Financial Performance: Hinge Health’s income statement for Q1 2025 reflects robust growth, with revenue rising 50% to USD 123.8 million from USD 82.7 million in Q1 2024, driven by existing client expansion, while cost of revenue decreased by 5% to USD 23.6 million due to lower inventory costs, boosting gross profit by 73% to USD 100.2 million and improving gross margin to 81%. Operating expenses showed mixed trends: research and development costs dropped 21% to USD 23.5 million due to reduced headcount from the 2024 restructuring, while sales and marketing expenses rose 11% to USD 46.7 million to support growth initiatives; general and administrative expenses slightly decreased by 3% to USD 16.9 million, reflecting cost efficiencies despite public company preparation costs. These financial dynamics, alongside a net income of USD 17.1 million in Q1 2025 compared to a net loss of USD 26.5 million in Q1 2024, highlight Hinge Health’s improving profitability and operational efficiency amidst its strategic expansion efforts.

Key Management Highlights

Risk Associated (High)

Investment in the IPO of “HNGE” is exposed to a variety of risks such as:

• Dependence on Client Retention and Expansion: Hinge Health’s growth relies heavily on retaining its 2,250 clients and expanding its 20 million contracted lives as of December 31, 2024, with a 98% retention rate and 117% NDR, but failure to maintain high client satisfaction (NPS of 87) or successfully upsell new programs like women’s pelvic health could hinder revenue growth, especially as it enters new markets like Medicare Advantage.
• Challenges in Scaling AI-Driven Technology: The company’s AI-powered platform, including TrueMotion and HingeConnect, reduced care team hours by 95% in 2024, but scaling these technologies internationally—starting with Canada in 2024 and Europe in 2025—may face regulatory hurdles, data integration issues, or higher R&D costs, potentially impacting operational efficiency and margins, which improved to 81% in Q1 2025.
• Financial Pressures from Restructuring and Expansion: Despite a revenue increase to USD 123.8 million in Q1 2025, the 2024 restructuring plan, which cut 10% of the workforce and incurred USD 7.5 million in charges, alongside rising sales and marketing costs (up 11% to USD 46.7 million), could strain financial resources if international expansion or new market entries do not yield expected returns, especially given a historical net loss of USD 11.9 million in 2024.

Conclusion

Hinge Health (HNGE), a digital health company specializing in AI-driven musculoskeletal (MSK) care, is offering 13,666,000 shares in its initial public offering, with an option for selling stockholders to offer an additional 2,049,309 shares of Class A common stock, expecting net proceeds of approximately USD 230.7 million at an assumed price of USD 30.00 per share as of May 16, 2025. The company, which automates personalized MSK treatment, reducing care hours by 95% and addressing a USD 27 billion U.S. market, plans to allocate USD 268.2 million of proceeds to tax obligations for RSU settlements, with remaining funds supporting general corporate purposes and growth strategies, though it retains discretion over their use and does not anticipate paying dividends. HNGE’s financials show a 50% revenue increase to USD 123.8 million in Q1 2025, a gross margin of 81%, and a net income of USD 17.1 million, but risks include client retention challenges, international scaling hurdles, and financial pressures from restructuring, which may impact its growth trajectory in a USD 1.3 trillion MSK burden market.

Hence, given the financial performance of the company, use of proceeds, and associated risks “Hinge Health (HNGE)” IPO seems “Neutral" at the IPO price.